CRABP2 and neoplasm: A single study suggested CRABP2 to acts as a tumor inhibitor in esophageal carcinoma (Yang et al. 2016), while in breast cancer, CRABP2 can both suppress or promote tumor invasion depending on tumor type (Feng et al. 2019).